Compare Enveric Biosciences Inc (ENVB) vs Trade Desk Inc (TTD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Trade Desk Inc — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Trade Desk Inc trades at $12.36 (market cap $5.72B). The key difference: Trade Desk Inc is far larger — about 855× Enveric Biosciences Inc's market cap, and Enveric Biosciences Inc is more actively traded (41,141 versus 14,380,236). Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Trade Desk Inc for 72 Days on average.
| ENVB | TTD | |
|---|---|---|
Market Cap | $6.69M | $5.72B |
Volume | 41,141 | 14,380,236 |
Sector | Health | Media |
52-Week High | $10.80 | $54.13 |
52-Week Low | $1.27 | $11.92 |
Typical Hold Time | 14 Days | 72 Days |
Enterprise Value | -$1.60M | $4.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
TTD trades at $12.34, down 3.52% today and 68% year-to-date, reflecting bearish technical signals and recent earnings misses. Revenue grew to $2.90B in 2025 with a 15.3% net margin, but 2026 guidance indicates slowing growth. The stock faces pressure from competition and index removal flows, with analyst consensus at a $14.72 price target amid mixed sentiment.
Outlook remains cautious due to competitive threats and slowing revenue growth, though valuation ratios appear low. Key risks include execution challenges and macroeconomic headwinds, while potential upside hinges on market share retention and cost management improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
